Pembroxim is a prescription cancer immunotherapy injection containing Pembrolizumab, a programmed death receptor-1 (PD-1) blocking humanized monoclonal IgG4 kappa antibody. Pembroxim is indicated for adults with certain types of advanced cancer including melanoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and gastric cancer. Each vial contains 100 mg of Pembrolizumab in 4 ml of solution, administered as a slow intravenous infusion. Order Pembroxim at PakMeds with a valid oncologist prescription.

Pembroxim Ingredients and Usage

Pembroxim contains Pembrolizumab, a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa, produced in recombinant Chinese hamster ovary (CHO) cells under controlled biopharmaceutical manufacturing conditions. It belongs to the drug class of PD-1 inhibitors, a subset of immune checkpoint inhibitors. Pembrolizumab was first approved by the FDA in September 2014 and is listed on the World Health Organization’s List of Essential Medicines.

Pembroxim is indicated for the treatment of multiple advanced and metastatic cancers. Key indications include unresectable or metastatic melanoma, head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma, gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer (NSCLC) expressing PD-L1, and microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumours across multiple tissue types. Pembroxim is used when cancer has spread, cannot be removed by surgery, or has not responded to prior treatment.

Pembroxim is administered as a slow intravenous infusion over 30 minutes, typically every 3 weeks or every 6 weeks depending on the cancer type and the treating oncologist’s prescribed protocol. Each 1 mL of solution contains 25 mg of Pembrolizumab. The dose for most adult indications is either 200 mg every 3 weeks or 400 mg every 6 weeks, continued until disease progression, unacceptable toxicity, or up to 24 months without disease progression.

How Does Pembroxim Work?

PD-1 (programmed death receptor-1) is an immune checkpoint protein expressed on the surface of T-cells. Under normal conditions, the PD-1 receptor binds to PD-L1 and PD-L2 ligands present on healthy cells, sending a suppressive signal that prevents T-cells from mounting an immune attack against the body’s own tissues. Cancer cells exploit this mechanism by overexpressing PD-L1, effectively disguising themselves and instructing T-cells to stand down, allowing tumours to grow unchecked.

Pembroxim binds with high affinity and selectivity to the PD-1 receptor on T-cells, physically blocking PD-L1 and PD-L2 from attaching. This removes the suppressive immune checkpoint signal, restoring T-cell activity and enabling the immune system to recognize and destroy cancer cells. Pembroxim also promotes T-cell proliferation and increases cytokine production within the tumour microenvironment. In the KEYNOTE-006 trial, Pembrolizumab produced a 74.1% twelve-month survival rate in advanced melanoma patients, compared to 58.2% for ipilimumab. In patients with NSCLC expressing PD-L1 at a tumour proportion score above 50%, Pembrolizumab extended median overall survival to 17.3 months versus 8.2 months for standard docetaxel chemotherapy.

In 2017, the FDA designated Pembrolizumab the first tissue-agnostic oncology drug in history, approving it for any unresectable or metastatic solid tumour with mismatch repair deficiency or microsatellite instability, based on tumour genetics rather than the site of origin. Pembroxim’s Pembrolizumab molecule was produced using recombinant CHO cell technology to ensure consistent antibody structure and PD-1 binding affinity across manufacturing batches.

Pembroxim Side Effects

Pembroxim activates the immune system broadly, which can cause it to act against healthy tissues and organs in addition to tumour cells. Immune-mediated adverse reactions can affect any organ system and may occur at any time during treatment or after the final dose. The most commonly reported adverse reactions from Pembrolizumab clinical trials as a single agent include the following.

• Fatigue and generalised weakness
• Musculoskeletal pain including joint and muscle aches
• Skin rash and redness
• Pruritus (persistent itching)
• Diarrhoea, nausea, vomiting, and abdominal pain
• Decreased appetite and unintended weight loss
• Constipation
• Fever (pyrexia)
• Persistent cough and dyspnoea (shortness of breath)
• Hypothyroidism — reduced thyroid hormone output detected by blood test
• Elevated liver enzymes indicating immune-mediated hepatitis
• Elevated blood glucose including new onset or worsening diabetes
• Infusion reactions: chills, flushing, fever, hypotension, or wheezing during or after intravenous administration

Warnings

• Immune-mediated adverse reactions: Pembroxim can trigger serious or fatal immune-mediated inflammation in the lungs (pneumonitis), colon (colitis), liver (hepatitis), kidneys (nephritis), pituitary gland (hypophysitis), thyroid gland, and adrenal glands. These reactions can occur during treatment or weeks after the final dose. All patients require regular blood, liver, kidney, and thyroid function monitoring throughout the treatment course and after discontinuation.
• Infusion reactions: Serious and potentially life-threatening infusion reactions can occur during Pembroxim administration. Clinical staff must monitor vital signs throughout the infusion and be prepared to slow, interrupt, or permanently discontinue it as required. Patients must receive Pembroxim only in a supervised clinical or hospital setting.
• Pregnancy — women: Pembroxim can cause fetal harm by disrupting the PD-L1 mediated immune tolerance mechanism that protects the fetus during pregnancy, increasing the risk of miscarriage and stillbirth. Women of childbearing potential must use effective contraception during treatment and for at least 4 months after the final dose. A negative pregnancy test is required before starting therapy.
• Pregnancy — men: Male patients with partners capable of becoming pregnant must use effective contraception during Pembroxim treatment and for at least 3 months after the final dose.
• Breastfeeding: Breastfeeding is contraindicated during Pembroxim treatment and for 4 months after the final dose due to the risk of serious adverse reactions in the nursing infant.
• Drug interaction — thalidomide analogues: Pembroxim must not be combined with lenalidomide, pomalidomide, or thalidomide. Increased mortality has been reported in multiple myeloma patients receiving Pembrolizumab alongside these agents and dexamethasone.
• Organ and stem cell transplant patients: Pembroxim significantly raises the risk of organ transplant rejection. Patients who have received or are planned to receive an allogeneic haematopoietic stem cell transplant face a risk of severe graft-versus-host disease (GVHD), which can be life-threatening. A careful benefit-risk assessment is required before initiating Pembroxim in this population.
• Pre-existing autoimmune conditions: Patients with Crohn’s disease, ulcerative colitis, lupus, myasthenia gravis, Guillain-Barré syndrome, or any other autoimmune condition must disclose their history to their oncologist before receiving Pembroxim, as treatment may substantially worsen these conditions.
• Elevated blood sugar and lipids: Pembroxim can raise blood glucose levels and increase cholesterol and triglycerides. Patients with diabetes or existing lipid disorders require additional monitoring during treatment.
• Elderly patients: Patients aged 65 and above may experience side effects with greater severity. Closer clinical follow-up and more frequent monitoring are recommended for older patients.
• Prescription only: Pembroxim is a specialist oncology medicine available on prescription only. It must be prescribed by a qualified oncologist and administered by trained healthcare personnel in a clinical or hospital setting. Self-administration is not appropriate for this product.

Pembroxim Storage Conditions

Store Pembroxim vials under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze the vials and do not shake them, as mechanical agitation may degrade the antibody structure and reduce potency. Keep vials in the original carton to protect them from direct light until the point of use.

Once diluted for intravenous infusion, the prepared solution is stable at room temperature up to 25°C (77°F) for a maximum of 6 hours, or refrigerated at 2°C to 8°C for up to 24 hours from the time of dilution. The diluted solution must be used within these time windows. Pembroxim is a single-use, preservative-free formulation — any unused portion remaining in the vial after preparation must be discarded and must not be stored for reuse. Keep all vials out of reach of children and away from heat sources at all times.